Menu
Home
People
Places
Arts
History
Plants & Animals
Science
Life & Culture
Technology
Reference.org
Repotrectinib
open-in-new
<p>Repotrectinib, sold under the brand name Augtyro, is an <a href="/facts/Anti-cancer_medication/fWTLbaUT">anti-cancer medication</a> used for the treatment of <a href="/facts/Non-small_cell_lung_cancer/9T47knRp">non-small cell lung cancer</a>. It is taken <a href="/facts/By_mouth/vNQcvLVx">by mouth</a>. Repotrectinib is an inhibitor of <a href="/facts/ROS1/9KUrX9sv">proto-oncogene tyrosine-protein kinase ROS1</a> (<i>ROS1</i>) and of the <a href="/facts/Trk_receptor/y2oIVrRx">tropomyosin receptor tyrosine kinases</a> (TRKs) TRKA, TRKB, and TRKC. </p><p>The most common adverse reactions include <a href="/facts/Dizziness/eI8UvmS5">dizziness</a>, <a href="/facts/Dysgeusia/37AmaEg6">dysgeusia</a>, <a href="/facts/Peripheral_neuropathy/2KjA7nyD">peripheral neuropathy</a>, <a href="/facts/Constipation/l4DHHM6L">constipation</a>, <a href="/facts/Dyspnea/1jBfFzxU">dyspnea</a>, <a href="/facts/Ataxia/suENWGS6">ataxia</a>, <a href="/facts/Fatigue/C2oo4Hvg">fatigue</a>, <a href="/facts/Cognitive_disorders/PAhmL2df">cognitive disorders</a>, and <a href="/facts/Muscular_weakness/U9wAgeLn">muscular weakness</a>. </p><p>Repotrectinib was approved for medical use in the United States in November 2023, and in the European Union in January 2025. </p>